Marie C D Stoner1, Bellington Vwalika2, Marcela C Smid3, Shalin George2, Benjamin H Chi3, Elizabeth M Stringer3, Jeffrey S A Stringer4. 1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: stonerm@email.unc.edu. 2. Department of Obstetrics and Gynecology, University of Zambia School of Medicine, Lusaka, Zambia. 3. Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
OBJECTIVE: To investigate the association between HIV, antiretroviral therapy (ART), and pregnancy-associated hypertension (PAH) in an HIV-endemic setting. METHODS: A retrospective cohort study was undertaken of pregnant women for whom information was recorded between February 2006 and December 2012 in the Zambia Electronic Perinatal Record System, which captures data from 25 facilities in Lusaka, Zambia. PAH was defined as eclampsia, pre-eclampsia, hypertension, or elevated blood pressure (>140/80mm Hg) during delivery admission. Logistic regression estimated the odds of PAH among women by HIV serostatus, and by most recent CD4 T lymphocyte count and ART status among women with HIV infection. RESULTS: Among 249 771 women included in the analysis, 5354 (2.1%) had PAH. Compared with women without HIV infection, women with HIV infection not receiving ART had lower odds of PAH (adjusted odds ratio [AOR] 0.86, 95% confidence interval 0.78-0.95), whereas those with HIV infection who had initiated ART had higher odds of PAH (AOR 1.15, 95% CI 1.01-1.32). No association was found between PAH and timing of ART initiation or CD4 lymphocyte count. CONCLUSION: In a large African urban cohort, women with untreated HIV infection had the lowest odds of PAH. Treatment with ART could increase PAH risk beyond that of women without HIV infection and those with untreated infection. Published by Elsevier Ireland Ltd.
OBJECTIVE: To investigate the association between HIV, antiretroviral therapy (ART), and pregnancy-associated hypertension (PAH) in an HIV-endemic setting. METHODS: A retrospective cohort study was undertaken of pregnant women for whom information was recorded between February 2006 and December 2012 in the Zambia Electronic Perinatal Record System, which captures data from 25 facilities in Lusaka, Zambia. PAH was defined as eclampsia, pre-eclampsia, hypertension, or elevated blood pressure (>140/80mm Hg) during delivery admission. Logistic regression estimated the odds of PAH among women by HIV serostatus, and by most recent CD4 T lymphocyte count and ART status among women with HIV infection. RESULTS: Among 249 771 women included in the analysis, 5354 (2.1%) had PAH. Compared with women without HIV infection, women with HIV infection not receiving ART had lower odds of PAH (adjusted odds ratio [AOR] 0.86, 95% confidence interval 0.78-0.95), whereas those with HIV infection who had initiated ART had higher odds of PAH (AOR 1.15, 95% CI 1.01-1.32). No association was found between PAH and timing of ART initiation or CD4 lymphocyte count. CONCLUSION: In a large African urban cohort, women with untreated HIV infection had the lowest odds of PAH. Treatment with ART could increase PAH risk beyond that of women without HIV infection and those with untreated infection. Published by Elsevier Ireland Ltd.
Authors: Anna Suy; Esteban Martínez; Oriol Coll; Montserrat Lonca; Montserrat Palacio; Elisa de Lazzari; María Larrousse; Ana Milinkovic; Sandra Hernández; José L Blanco; Josep Mallolas; Agathe León; Juan A Vanrell; José M Gatell Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: R C Wimalasundera; N Larbalestier; J H Smith; A de Ruiter; S A McG Thom; A D Hughes; N Poulter; L Regan; G P Taylor Journal: Lancet Date: 2002-10-12 Impact factor: 79.321
Authors: Benjamin H Chi; Bellington Vwalika; William P Killam; Chibesa Wamalume; Mark J Giganti; Reuben Mbewe; Elizabeth M Stringer; Namwinga T Chintu; Nande B Putta; Katherine C Liu; Carla J Chibwesha; Dwight J Rouse; Jeffrey S A Stringer Journal: Int J Gynaecol Obstet Date: 2011-05 Impact factor: 3.561
Authors: Tabassum Firoz; Harshad Sanghvi; Mario Merialdi; Peter von Dadelszen Journal: Best Pract Res Clin Obstet Gynaecol Date: 2011-05-17 Impact factor: 5.237
Authors: P Stratton; R E Tuomala; R Abboud; E Rodriguez; K Rich; J Pitt; C Diaz; H Hammill; H Minkoff Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-02-01
Authors: Elizabeth M Stringer; Moses Sinkala; Jeffrey S Stringer; Elizabeth Mzyece; Ida Makuka; Robert L Goldenberg; Pascal Kwape; Martha Chilufya; Sten H Vermund Journal: AIDS Date: 2003-06-13 Impact factor: 4.177
Authors: Michele K Saums; Caroline C King; Jenna C Adams; Anandi N Sheth; Martina L Badell; Marisa Young; Lynn M Yee; Ellen G Chadwick; Denise J Jamieson; Lisa B Haddad Journal: Obstet Gynecol Date: 2019-12 Impact factor: 7.661
Authors: Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier Journal: Curr HIV/AIDS Rep Date: 2021-01-05 Impact factor: 5.071
Authors: Kristi R Van Winden; Allison Bearden; Naoko Kono; Toni Frederick; Eva Operskalski; Alice Stek; Raj Pandian; Lorayne Barton; Andrea Kovacs Journal: Am J Perinatol Date: 2019-07-31 Impact factor: 3.079
Authors: Joan T Price; Bellington Vwalika; Jessie K Edwards; Stephen R Cole; Margaret P Kasaro; Katelyn J Rittenhouse; Andrew Kumwenda; Mwansa K Lubeya; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2021-06-01 Impact factor: 3.771
Authors: Olga Tymejczyk; Marie Marcelle Deschamps; Vanessa Rouzier; Margaret L McNairy; Robert N Peck; Line Malha; Youry Macius; Daniel W Fitzgerald; Jean W Pape; Denis Nash Journal: J Clin Hypertens (Greenwich) Date: 2022-02-07 Impact factor: 3.738